Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .
How does short-term low-dose simvastatin influence serum prohepcidin levels in patients with end-stage renal disease? A pilot study.
Anemia is a common clinical problem in end-stage renal disease ( ESRD ) . Despite adequate erythropoiesis-stimulating agent ( ESA ) supplementation , some ESRD patients still have suboptimal hemoglobin levels , and iron deficiency and inflammation are recognized as the two most common causes . Hepcidin , a newly discovered key regulator of iron homeostasis , is found to be accumulated in ESRD . As it controls iron uptake and release , better reflecting real-time iron dem and and availability , hepcidin might become a target in the management of iron deficiency and ESA resistance in dialysis patients . For their pleiotropic functions apart from lipid-modulation , statins are also used as anti-inflammatory or immune-modulating agents . In this study , we applied simvastatin for the purpose of influencing serum prohepcidin level in a group of maintenance hemodialysis patients . Thirty-three ESRD patients undergoing hemodialysis were enrolled and assigned to experimental and hemodialysis control groups according to their lipid profile . Nineteen healthy adults were chosen as a normal control group . The subjects in the experimental group took 20 mg simvastatin orally per night for eight weeks , and those in the hemodialysis control group took no statins or any other lipid-modulating drugs . Before and after the experiment , the serum prohepcidin concentrations , plasma IL-6 , and serum C-reactive protein ( CRP ) , ferritin , hemoglobin , albumin , total cholesterol , glycerinate , and LDL and HDL cholesterol levels were determined . Of the 33 hemodialysis patients , the serum prohepcidin concentration was ( 175.8 + /- 52.9 ) ng/mL , significantly higher than that in the normal control group ( 149.5 + /- 24.2 ) ng/mL ( P = 0.048 ) . In the experimental group , the serum prohepcidin level was ( 156.7 + /- 51.9 ) ng/mL before treatment , and ( 190.6 + /- 49.6 ) ng/mL after eight weeks ( P = 0.127 ) . In the hemodialysis control group , the serum prohepcidin level was ( 190.6 + /- 49.6 ) ng/mL at the beginning , and ( 193.5 + /- 36.0 ) ng/mL after eight weeks ( P = 0.728 ) . In the experimental group , after taking simvastatin for eight weeks the serum total cholesterol and triglyceride levels had lowered by 18.6 % ( P = 0.004 ) and 55.1 % ( P = 0.007 ) , respectively . The plasma IL-6 , serum CRP , ferritin , hemoglobin , albumin , and LDL and HDL cholesterol levels in both the hemodialysis group remained unchanged . According to our preliminary study , eight weeks of 20 mg simvastatin did not significantly change the serum prohepcidin , high-sensitive CRP , or IL-6 concentrations in the group of maintenance hemodialysis patients
Our meta‐ analysis showed beneficial effects  of statin use  on reducing inflammatory markers in patients with MetS and related disorders
& NA ; Current evidence suggests that statin use decreases the incidence of cardiovascular diseases ( CVD ) through reducing LDL cholesterol and decreasing inflammation .
Metabolic syndrome ( MetS ) is usually associated with increased inflammatory markers and increased risk of CVD .